XNAS · GANX
+1.12% · +$0.0201 · Vol 589.4K
Market closed · last close 4:00 PM ET · price as of 19:47:50 ET
Gain Therapeutics, Inc. Common Stock

Gain Therapeutics, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$1.81
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is GANX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for GANX are being assembled.
About Gain Therapeutics, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
21
Country
US

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.82
Day high
$1.87
Day low
$1.79
Previous close
$1.79
52W high
$2.38
-23.95% from high
52W low
$1.64
23% of range
Market cap
$76.4M
EPS
$-0.6300
Shares out
42.7M
Volume
589.4K
VWAP
$1.83
Price history computed in-house
1W
-3.72%
1M
+8.71%
SMA 50 $1.84 · below
SMA 200 $1.84 · below
52W position 23%
Veridion warehouse edge

Warehouse intelligence for GANX.

Veridion Score
66
0: 561: 372: 513: 704: 825: 60
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

GANX insider activity

Gain Therapeutics, Inc. Common Stock

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for GANX.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

GANX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for GANX in this window.
Lobbying spend

GANX lobbying filings, year to date.

Registered lobbying filings matched to Gain Therapeutics, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for GANX in this window.
Latest news · GANX
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for GANX.
Options
Sovereign unlock shows live options positioning for GANX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.